drugset

drugset / Trial / NCT03542669

Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

NCT03542669 ↗

Phase 1 Unknown 9 enrolled Peking University People's Hospital Beijing Weixiao Biotechnology Development Limited · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open, single-arm, phase I clinical trial to evaluate safety and efficacy and of 6b11-OCIK injection in the treatment of recurrent drug-resistant ovarian cancer

Timeline

Start: 2018-08-03
Primary completion: 2022-12-30
Completion: 2023-12-30

Publications

Cheng H, Ma R, Wang S, Wang Y, Li Y, Tang Z, Dou S, Wang Y, Zhu H, Ye X, Zhang T, Zhang Y, Li S, Zhao Y, Li Y, Cui H, Chang X. Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer. Front Immunol. 2021 Aug 2;12:707468. doi: 10.3389/fimmu.2021.707468. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	6B11-OCIK	Cell therapy	1e+09 cells	Intravenous
Subject	6B11-OCIK	Cell therapy	2e+09 cells	Intravenous
Background	Doxorubicin	Other / unclassified	30 mg/m2	Intravenous

Indications